Phase I single-ascending dose study of ASKP1240 (Anti-CD40 MAB) in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Bleselumab (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics; Pharmacokinetics
- 07 Dec 2012 Additional lead trial centre (Kyowa Hakko Kirin) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History